Editorials
Federally-registered compounding facilities stopped making tirzepatide on May 22. This transition is significant for patients, and we at PSM think there are four things you should be watching for.
Articles in Endpoints News and the Houston Chronicle raise questions about the regulatory process for 503B compounding facilities.
Partnership for Safe Medicines released the following statement in response to the advertisement that lifestyle brand Hims & Hers released ahead of the Super Bowl to sell unregulated compounded weight loss drugs
Colorado submitted its application to the FDA to import medicine from Canada on December 5. Like other Canadian importation plans, this one isn’t safe and it’s unlikely to save money.
This editorial by Peter J. Pitts was published in The Times Weekly on March 3, 2020. Mr. Pitts is president of the Center for Medicine in the Public Interest and a former FDA associate commissioner. Keep Canadian drugs out of U.S. medicine cabinets The Trump administration recently proposed two rules that would allow states, pharmacies, and drug wholesalers to import non-FDA approved medicines from Canada. No administration, Republican or Democrat, has ever allowed Canadian drug importation – and for good reason. First, experts agree that such a scheme wouldn’t reduce by one penny the co-pay of a single American. Second,…